A bill to amend title XVIII of the Social Security Act to provide for payment under the prospective payment system for hospital outpatient department services under the medicare program for new drugs administered in such departments as soon as the drugs administered in such departments as soon as the drug is approved for marketing by the Commissioner of Food and Drugs.

Summary

Amends title XVIII (Medicare) of the Social Security Act (SSA) to provide for Medicare pass-through payment under the prospective payment system for hospital outpatient department (OPD) services for certain new drugs or biologicals beginning on the first date on which such a drug or biological is furnished as an OPD service after its approval by the Secretary of Health and Human Services for marketing.

This text is taken from the official record. PoliticalRepo does not editorialize.

Timeline

1. 25 July 2002

   Introduced

   Read twice and referred to the Committee on Finance.

   Source: IntroReferral

2. 25 July 2002

   Introduced

   Sponsor introductory remarks on measure. (CR S7374)

   Source: IntroReferral

3. 25 July 2002

   Introduced

   Introduced in Senate

   Source: IntroReferral

Votes

No vote records are attached yet.

Versions

• Introduced in Senate · 25 July 2002 · Official file

Documents

3 official files

• Introduced in Senate (text)

  Introduced in Senate · EN · 25 July 2002

  ViewDownloadOpen at official source

• Introduced in Senate (PDF)

  Introduced in Senate · EN · 25 July 2002

  ViewDownloadOpen at official source

• Introduced in Senate

  summary · EN · 25 July 2002

  Open at official source

Sponsors

• Sen. Kerry, John F. [D-MA] · D · Sponsor
• Sen. Kennedy, Edward M. [D-MA] · D · Cosponsor
• · ssfi00 · Standing

Related records

• related to → To amend title XVIII of the Social Security Act to provide for payment under the prospective payment system for hospital outpatient department services under the Medicare Program for new drugs administered in such departments as soon as the drug is approved for marketing by the Commissioner of Food and Drugs.